CLAIMS

We claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable derivative thereof,
wherein:
A-B is N-O or O-N;
R^1 is selected from halogen, NO_2, T_yR, or TCN;
each T is independently selected from an optionally substituted C_1-C_6 alkylidene chain, wherein:
one methylene unit of T is optionally replaced by O, NR, NRC(O), C(O)NR, NRC(O)NR, C(O), $C(O)CH_2C(O)$, C(O)C(O), C(O)O, OC(O), $NRSO_2$, S, SO, SO_2NR, or SO_2;
y is zero or one;
each R is independently selected from hydrogen or an optionally substituted C_1-C_6 aliphatic group, or:
two R on the same nitrogen are taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 1-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur;
R^2 is R or Ar^1;
G is selected from X_mR or X_mAr^1;

each m is independently selected from zero or one;

X is selected from O, S, SO, SO_2, NH, C(O), C(O)NH, NHC(O), NHC(O)NH, SO_2NH, $NHSO_2$, or $NHSO_2NH$;

each Ar^1 is independently selected from an optionally substituted ring selected from a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^3 is selected from ZQ_nR^5 or ZQ_nR^7, wherein ZQ_nR^7 is not hydrogen;

Q is an optionally substituted C_1-C_6 alkylidene chain wherein:

one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, NRC(O), C(O)NR, C(O), S, SO, SO_2, or SO_2NR;

provided that said optionally replaced methylene unit of Q is a methylene unit non-adjacent to R^7;

each n is independently selected from zero or one;

Z is selected from a valence bond, O, S, SO, SO_2, NH, C(O), C(O)NH, NHC(O), SO_2NH, or $NHSO_2$;

R^4 is selected from R, halogen, NO_2, CN, OR, SR, $N(R)_2$, NRC(O)R, $NRC(O)N(R)_2$, $NRCO_2R$, C(O)R, CO_2R, OC(O)R, $C(O)N(R)_2$, $OC(O)N(R)_2$, SOR, SO_2R, $SO_2N(R)_2$, $NRSO_2R$, $NRSO_2N(R)_2$, C(O)C(O)R, or $C(O)CH_2C(O)R$, or:

two R^4 on adjacent positions of the phenyl ring are taken together to form a saturated, partially unsaturated, or fully unsaturated 5-7 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

R^5 is Ar^1, wherein R^5 is optionally substituted with up to three R^6;

each R^6 is independently selected from R, halogen, NO_2, CN, OR, SR, $N(R)_2$, $NRC(O)R$, $NRC(O)N(R)_2$, $NRCO_2R$, $C(O)R$, CO_2R, $C(O)N(R)_2$, $OC(O)N(R)_2$, SOR, SO_2R, $SO_2N(R)_2$, $NRSO_2R$, $NRSO_2N(R)_2$, $C(O)C(O)R$, or $C(O)CH_2C(O)R$, or:

two R^6 on adjacent positions of R^5 are taken together to form a saturated, partially unsaturated, or fully unsaturated 5-7 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

R^7 is selected from R, halogen, NO_2, CN, OR, SR, $N(R)_2$, $NRC(O)R$, $NRC(O)N(R)_2$, $NRCO_2R$, $C(O)R$, CO_2R, $OC(O)R$, $C(O)N(R)_2$, $OC(O)N(R)_2$, SOR, SO_2R, $SO_2N(R)_2$, $NRSO_2R$, $NRSO_2N(R)_2$, $C(O)C(O)R$, or $C(O)CH_2C(O)R$;

provided that:

(a) when R^3 is ZQR^7, R^1 is other than hydrogen , and

(b) when R^1 is hydrogen, R^5 is other than phenyl.

2. The compound according to claim 1, wherein said compound has the formula **Ia** or **Ib**:



Ia **Ib**

or a pharmaceutically acceptable derivative thereof.

3. The compound according to claim 2, wherein said compound has the formula **II**:



II

or a pharmaceutically acceptable derivative thereof.

4. The compound according to claim 3 wherein:

R^3 is ZQ_nR^5;

Z is a valence bond, O, NH, or NHC(O); and

R^5 is a 5-6 membered saturated or aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with up to two R^6 groups.

5. The compound according to claim 3, wherein:

R^3 is ZQ_nR^7;

Z is a valence bond, O, NH, or NHC(O); and

R^7 is selected from OR, $N(R)_2$, OC(O)R, CO_2R, $C(O)N(R)_2$, NRC(O)OR, or NRC(O)R.

6. The compound according to claim 2, wherein said compound has the formula **IIIa**:



IIIa

or a pharmaceutically acceptable derivative thereof.

7. The compound according to claim 6, wherein:

n is one;

Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and

R^5 is a 5-6 membered saturated or aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with up to two R^6 groups.

8. The compound according to claim 2, wherein said compound has the formula **IIIb**:



IIIb

or a pharmaceutically acceptable derivative thereof.

9. The compound according to claim 8, wherein:

n is one;

Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and

R^7 is selected from OR, $N(R)_2$, OC(O)R, CO_2R, $C(O)N(R)_2$, NRC(O)OR, or NRC(O)R.

10. The compound according to claim 2, wherein said compound has the formula **IVa**:



IVa

or a pharmaceutically acceptable derivative thereof.

11. The compound according to claim 10, wherein:
n is one;
Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and
R^5 is a 5-6 membered saturated or aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with up to two R^6 groups.

12. The compound according to claim 1, wherein said compound has the formula **IVb**:



IVb

or a pharmaceutically acceptable derivative thereof.

13. The compound according to claim 12, wherein:
n is one;

Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and

R^7 is selected from OR, $N(R)_2$, OC(O)R, CO_2R, $C(O)N(R)_2$, NRC(O)OR, or NRC(O)R.

14. The compound according to claim 2, wherein said compound has the formula **Va**:



Va

or a pharmaceutically acceptable derivative thereof.

15. The compound according to claim 14, wherein:

n is one;

Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and

R^5 is a 5-6 membered saturated or aryl ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with up to two R^6 groups.

16. The compound according to claim 2, wherein said compound has the formula **Vb**:



Vb

or a pharmaceutically acceptable derivative thereof.

17. The compound according to claim 16, wherein:
n is one;
Q is a C_{1-6} alkylidene chain wherein one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, S, or C(O); and
R^7 is selected from OR, $N(R)_2$, OC(O)R, CO_2R, $C(O)N(R)_2$, NRC(O)OR, or NRC(O)R.

18. The compound according to any of claims 4, 5, 7, 9, 11, 13, 15, or 17, wherein:
G is X_mR or X_mAr^1;
each m is independently zero or one;
each X is independently selected from O, S, or NH;
R is C_{1-4} aliphatic; and
Ar^1 is an optionally substituted 5-6 membered saturated or aryl ring having 0-2 heteroaroms independently selected from nitrogen, oxygen, or sulfur.

19. The compound according to claim 1, wherein said compound is selected from the following Table 1 compounds:



II

Table 1. Compounds of Formula II

No.	R^1		
II-1	CH_3		
II-2	CH_3		
II-3	CH_3		
II-4	CH_3		

No.	R^1		
II-5	CH_3		
II-6	CH_2CN		
II-7	COOH		
II-8	H		
II-9	CH_2CH_3		
II-10	$C(O)NH_2$		

20. The compound according to claim 1, wherein said compound is selected from the following Table 2 compounds:



IIIa

Table 2. Compounds of Formula **IIIa**

No.	R^1		
IIIa-1	H		
IIIa-2	H		
IIIa-3	H		
IIIa-4	H		
IIIa-5	H		

No.	R^1		
IIIa-6	H		
IIIa-7	H		
IIIa-8	H		
IIIa-9	H		
IIIa-10	H		
IIIa-11	H		
IIIa-12	H		

No.	R^1		
IIIa-13	H		
IIIa-14	H		
IIIa-15	H		
IIIa-16	H		
IIIa-17	H		
IIIa-18	H		
IIIa-19	H		

No.	R^1		
IIIa-20	H		
IIIa-21	H		
IIIa-22	H		
IIIa-23	H		
IIIa-24	H		
IIIa-25	H		

No.	R^1		
IIIa-26	H		
IIIa-27	H		
IIIa-28	H		
IIIa-29	H		
IIIa-30	H		
IIIa-31	H		
IIIa-32	CH_3		

No.	R^1		
IIIa-33	CN		
IIIa-34	H		
IIIa-35	H		
IIIa-36	CH_3		
IIIa-37	CH_3		
IIIa-38	CH_3		
IIIa-39	CH_3		

No.	R^1		
IIIa-40			
IIIa-41	OH		
IIIa-42	CH_3		
IIIa-43	H		
IIIa-44	H		
IIIa-45	H		
IIIa-46	H		

21. The compound according to claim 1, wherein said compound is selected from the following Table 3 compounds:



IIIb

Table 3. Compounds of Formula **IIIb**

No.	R^1		
IIIb-1	CH_3		
IIIb-2	CH_3		
IIIb-3	CH_2CH_3		
IIIb-4	CH_2OH		

No.	R^1		
IIIb-5	CH_3		
IIIb-6	CH_2CN		
IIIb-7	CH_2OH		
IIIb-8	CH_3		
IIIb-9	CH_3		
IIIb-10	CH_2OH		
IIIb-11	CH_3		

No.	R^1		
IIIb-12	CH_2CH_3		
IIIb-13	CH_3		
IIIb-14	CH_3		
IIIb-15	CH_3		
IIIb-16	CH_3		
IIIb-17	CH_3		
IIIb-18	CH_2OH		

No.	R^1		
IIIb-19	CH_2OH		
IIIb-20	CH_2OH		
IIIb-21	CH_2OH		
IIIb-22	CH_3		
IIIb-23	CO_2CH_3		
IIIb-24	CO_2H		
IIIb-25	CH_2OH		

No.	R^1		
IIIb-26	$C(O)NH_2$		
IIIb-27	CN		
IIIb-28	CH_3		
IIIb-29	$CH_2OCH_2CH_2CH_3$		

22. The compound according to claim 1, wherein said compound is selected from the following Table 4 compounds:



IVa

Table 4. Compounds of Formula **IVa**

No.	R^1		
IVa-1	H		
IVa-2	H		
IVa-3	H		
IVa-4	H		
IVa-5	CH_3		
IVa-6	CH_3		
IVa-7	CH_3		

No.	R^1		
IVa-8	CH_3		
IVa-9	H		
IVa-10	H		
IVa-11	H		
IVa-12	H		
IVa-13	CH_3		

No.	R^1		
IVa-14	CH_3		
IVa-15	CH_3		
IVa-16	CH_3		

23. The compound according to claim 1, wherein said compound is selected from the following Table 5 compounds:



IVb

Table 5. Compounds of Formula **IVb**

No.	R^1		

No.	R^1		
IVb-1	CH_3		
IVb-2	CH_2CH_3		
IVb-3	CH_3		
IVb-4	CH_2OH		
IVb-5	OH		
IVb-6	CH_2CH_3		
IVb-7	CH_2CN		

No.	R^1		
IVb-8			
IVb-9	NH_2		

24. The compound according to claim 1, wherein said compound is selected from the following Table 6 compounds:



Va

Table 6. Compounds of Formula **Va**

No.	R^1		
Va-1	H		

No.	R^1		
Va-2	H		
Va-3	H		
Va-4	CH_3		
Va-5	H		
Va-6	H		
Va-7	CH_2CH_3		
Va-8	CH_2CN		

No.	R^1		
Va-9	CH_2OH		
Va-10	H		
Va-11	H		
Va-12	H		
Va-13	CH_3		
Va-14	OH		

No.	R^1		
Va-15	H		
Va-16	NH_2		
Va-17	H		

25. The compound according to claim 1, wherein said compound is selected from the following Table 7 compounds:



Vb

Table 7. Compounds of Formula **Vb**

No.	R^1		

No.	R^1		
Vb-1	CH_3		
Vb-2	CH_2CH_3		
Vb-3	CH_3		
Vb-4	CH_2OH		
Vb-5	OH		
Vb-6	CH_2CH_3		
Vb-7	CH_2CN		

No.	R^1		
Vb-8	CH_2OH		
Vb-9	NH_2		
Vb-10	CH_2CN		
Vb-11	CH_2OH		
Vb-12	NH_2		
Vb-13	CH_2OH		
Vb-14	CH_3		

No.	R^1		
Vb-15	CH_2CH_3		
Vb-16	CH_3		
Vb-17	CH_2OH		
Vb-18	OCH_3		
Vb-19	CH_2OCH_3		
Vb-20	CH_3		
Vb-21	CH_2CH_3		

No.	R^1		
Vb-22	CH_2OH		

26. A composition comprising a compound according to claim 1, in an amount to detectably inhibit Src or Lck protein kinase activity, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. The composition according to claim 26, additionally comprising an additional therapeutic agent selected from an a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder.

28. A method of inhibiting Src or Lck kinase activity in a biological sample, comprising the step of contacting said biological sample with:

a) a composition according to claim 26; or

b) a compound according to claim 1.

29. A method of treating or lessening the severity of a Src- or Lck-mediated disease or condition in a

patient, comprising the step of administering to said patient:

a) a composition according to claim 26; or

b) a compound according to claim 1.

30. The method according to claim 29, wherein said Src-mediated disease is selected from hypercalcemia, restenosis, osteoporosis, osteoarthritis, symptomatic treatment of bone metastasis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, lupus, graft vs. host disease, T-cell mediated hypersensitivity disease, Hashimoto's thyroiditis, Guillain-Barre syndrome, chronic obtructive pulmonary disorder, contact dermatitis, cancer, Paget's disease, asthma, ischemic or reperfusion injury, allergic disease, atopic dermatitis, or allergic rhinitis.

31. The method according to claim 29, wherein said Lck-mediated disease is selected from an autoimmune disease, allergies, rheumatoid arthritis, or leukemia.

32. The method according to claim 29, comprising the additional step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

33. A composition for coating an implantable device comprising a compound according to claim 1 and a carrier suitable for coating said implantable device.

34. An implantable device coated with a composition according to claim 33.